2023 World Conference on Lung Cancer (Posters)-EP12.01. Clinical Significance of Chronic Interstitial Pneumonia Induced by EGFR-TKI Administration

EP12.01. Clinical Significance of Chronic Interstitial Pneumonia Induced by EGFR-TKI Administration - PDF(Slides)

Pdf Summary

Chronic interstitial pneumonia is a potential complication of treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with EGFR mutation-positive lung cancer. However, there is limited information on the prevalence, course, and safety of continuing EGFR-TKI treatment in these cases. <br /><br />A retrospective study was conducted to evaluate the prevalence and outcomes of chronic interstitial pneumonia in patients receiving osimertinib or afatinib as a first-line treatment for EGFR mutation-positive non-small cell lung cancer. The study included 92 patients, and 5% of them exhibited chronic progression of interstitial pneumonia. The overall response rate to EGFR-TKIs among these patients was 80%, with one patient discontinuing treatment due to drug-related pneumonitis. <br /><br />The study also investigated the imaging patterns and risk factors associated with chronic interstitial pneumonia induced by EGFR-TKI treatment. The absence of a diffuse alveolar damage pattern suggested that the administration of EGFR-TKIs can be relatively safe. Pre-existing interstitial lung abnormalities were not identified as a risk factor in these cases. <br /><br />Pathological examination revealed fibrosis and lymphocyte infiltration in one patient, and the interstitial pneumonia improved after discontinuing the drug. The other four patients did not experience acute progression of interstitial pneumonia. <br /><br />In conclusion, chronic interstitial pneumonia can occur in a small percentage of patients receiving EGFR-TKI treatment for EGFR mutation-positive lung cancer. Clinicians should be cautious of this complication and evaluate the risk of continuing EGFR-TKI treatment. Further studies are needed to assess the risk factors and optimal management strategies for chronic interstitial pneumonia induced by EGFR-TKIs.

Asset Subtitle

Yuki Sato

Meta Tag

Speaker Yuki Sato

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Chronic interstitial pneumonia

EGFR-TKI treatment

epidermal growth factor receptor

tyrosine kinase inhibitors

EGFR mutation-positive lung cancer

osimertinib

afatinib

non-small cell lung cancer

prevalence

outcomes